X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (419) 419
Publication (79) 79
Conference Proceeding (38) 38
Patent (25) 25
Book Review (14) 14
Book Chapter (3) 3
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (259) 259
humans (239) 239
female (221) 221
oncology (205) 205
middle aged (167) 167
breast cancer (114) 114
breast neoplasms - drug therapy (110) 110
breast neoplasms - pathology (101) 101
aged (95) 95
antineoplastic combined chemotherapy protocols - therapeutic use (85) 85
chemotherapy (83) 83
adult (82) 82
chemotherapy, adjuvant (77) 77
disease-free survival (70) 70
abridged index medicus (66) 66
breast neoplasms - surgery (64) 64
cancer (62) 62
treatment outcome (60) 60
neoplasm staging (56) 56
tamoxifen (56) 56
follow-up studies (54) 54
prognosis (53) 53
tamoxifen - therapeutic use (53) 53
clinical trials (52) 52
fluorouracil - administration & dosage (50) 50
lymphatic metastasis (50) 50
breast neoplasms - mortality (47) 47
therapy (47) 47
male (46) 46
surgery (46) 46
article (44) 44
survival analysis (41) 41
combined modality therapy (40) 40
cyclophosphamide - administration & dosage (38) 38
mastectomy (36) 36
surgical adjuvant breast (35) 35
doxorubicin - administration & dosage (34) 34
randomized controlled trials as topic (34) 34
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
research (31) 31
care and treatment (30) 30
colonic neoplasms - pathology (30) 30
original reports (30) 30
risk factors (30) 30
antineoplastic agents, hormonal - therapeutic use (29) 29
colonic neoplasms - drug therapy (29) 29
clinical trials as topic (28) 28
fluorouracil (28) 28
medicine, general & internal (28) 28
women (28) 28
drug therapy (27) 27
risk (27) 27
survival (27) 27
breast neoplasms - radiotherapy (26) 26
radiotherapy (26) 26
tumors (26) 26
carcinoma (25) 25
human necessities (25) 25
hygiene (25) 25
medical or veterinary science (25) 25
adjuvant treatment (24) 24
proportional hazards models (24) 24
time factors (24) 24
breast neoplasms - prevention & control (23) 23
radiation-therapy (23) 23
breast neoplasms - metabolism (22) 22
leucovorin - administration & dosage (22) 22
mastectomy, segmental (22) 22
survival rate (22) 22
tamoxifen - administration & dosage (22) 22
breast neoplasms - therapy (21) 21
prospective studies (21) 21
trial (21) 21
diagnosis (20) 20
risk assessment (20) 20
cancer therapies (19) 19
health aspects (19) 19
lymph nodes - pathology (19) 19
random allocation (19) 19
recurrence (19) 19
trastuzumab (19) 19
antineoplastic combined chemotherapy protocols - administration & dosage (18) 18
incidence (18) 18
medicine & public health (18) 18
neoplasm recurrence, local (18) 18
patient outcomes (18) 18
quality of life (18) 18
breast neoplasms - chemistry (17) 17
postmenopausal women (17) 17
randomized-trial (17) 17
receptors, estrogen - analysis (17) 17
receptors, estrogen - metabolism (17) 17
tamoxifen - adverse effects (17) 17
taxoids - administration & dosage (17) 17
animals (16) 16
breast (16) 16
colonic neoplasms - mortality (16) 16
evaluation (16) 16
leucovorin (16) 16
neoplasm invasiveness (16) 16
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (446) 446
French (10) 10
German (3) 3
Spanish (3) 3
Chinese (2) 2
Arabic (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 927 - 933
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 156 - 163
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 25, pp. 3366 - 3373
Journal Article
Journal Article